[go: up one dir, main page]

CR20120359A - Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle) - Google Patents

Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle)

Info

Publication number
CR20120359A
CR20120359A CR20120359A CR20120359A CR20120359A CR 20120359 A CR20120359 A CR 20120359A CR 20120359 A CR20120359 A CR 20120359A CR 20120359 A CR20120359 A CR 20120359A CR 20120359 A CR20120359 A CR 20120359A
Authority
CR
Costa Rica
Prior art keywords
erythemate
sle
treatment
humanized antibodies
system lupus
Prior art date
Application number
CR20120359A
Other languages
English (en)
Inventor
Frank Osterroth
Christoph Uherek
Christoph Bruecher
Peter Roettgen
Benjamin Daelken
Andre Engling
Chantal Zuber
Niklas Czeloth
Original Assignee
Biotest Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0920940A external-priority patent/GB0920940D0/en
Priority claimed from GB0920942A external-priority patent/GB0920942D0/en
Priority claimed from GB0920933A external-priority patent/GB0920933D0/en
Application filed by Biotest Ag filed Critical Biotest Ag
Publication of CR20120359A publication Critical patent/CR20120359A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se proporciona un anticuerpo humanizado o quimérico o su frangmento, cpaz de ligar a interleucina-10 (IL-10), en donde el anticuerpo o su fragmento: (i) liga a la misma región de IL-10 que el receptor IL-10a (IL-10Ra) y no es capaz de ligar IL-10 cuando IL-10 se liga al receptor.
CR20120359A 2009-11-30 2012-06-28 Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle) CR20120359A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0920940A GB0920940D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920942A GB0920942D0 (en) 2009-11-30 2009-11-30 Agent for treating disease
GB0920933A GB0920933D0 (en) 2009-11-30 2009-11-30 Agent for treating disease

Publications (1)

Publication Number Publication Date
CR20120359A true CR20120359A (es) 2013-01-25

Family

ID=43798505

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20120359A CR20120359A (es) 2009-11-30 2012-06-28 Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle)
CR20120358A CR20120358A (es) 2009-11-30 2012-06-28 Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistémico eritematoso (sle)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20120358A CR20120358A (es) 2009-11-30 2012-06-28 Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistémico eritematoso (sle)

Country Status (17)

Country Link
US (4) US8852871B2 (es)
EP (2) EP2470208A1 (es)
JP (2) JP2013511994A (es)
KR (2) KR101802261B1 (es)
CN (2) CN102711829B (es)
AU (2) AU2010323037B2 (es)
BR (2) BR112012012912A2 (es)
CA (2) CA2782004A1 (es)
CO (1) CO6561779A2 (es)
CR (2) CR20120359A (es)
IL (2) IL219954A (es)
MX (2) MX343228B (es)
NZ (2) NZ600899A (es)
RU (2) RU2587622C2 (es)
SG (2) SG10201407935YA (es)
WO (2) WO2011064398A1 (es)
ZA (1) ZA201204843B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ600899A (en) 2009-11-30 2014-09-26 Biotest Ag Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)
CA2908198A1 (en) 2013-04-18 2014-10-23 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
WO2014176373A2 (en) * 2013-04-24 2014-10-30 Armo Biosciences, Inc. Interleukin-10 compositions and uses thereof
ES2688206T3 (es) 2013-06-17 2018-10-31 Armo Biosciences, Inc. Procedimiento de evaluación de la identidad y la estabilidad de proteínas
JP6509867B2 (ja) 2013-08-30 2019-05-08 アルモ・バイオサイエンシーズ・インコーポレイテッド 疾患及び障害を治療するためにインターロイキン−１０を使用する方法
WO2015070060A1 (en) 2013-11-11 2015-05-14 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US20160356794A1 (en) * 2014-02-10 2016-12-08 Merck Sharp & Dohme Corp. Antibodies that bind to human tau and assay for quantifying human tau using the antibodies
CN107430123B (zh) * 2014-11-28 2020-04-14 通用电气健康护理生物科学股份公司 用于在传感器表面上检测分析物-配体结合的方法
JP6944747B2 (ja) * 2014-12-15 2021-10-06 モルフォシス・アーゲー Ｉｌ−１７ｃに対する抗体
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
US20160361415A1 (en) 2015-05-28 2016-12-15 Armo Biosciences, Inc. Methods of Using Interleukin-10 for Treating Diseases and Disorders
EP4606387A3 (en) 2015-08-25 2025-11-19 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR102213790B1 (ko) 2015-12-04 2021-02-09 노파르티스 아게 항체 시토카인 그라프트된 조성물 및 면역조절을 위한 사용 방법
WO2019072566A1 (en) 2017-10-10 2019-04-18 Biotest Ag COMBINATION OF ANTI-IL10 AND ANTI-PD1 ANTIBODIES FOR THE TREATMENT OF CANCER
AR114112A1 (es) * 2018-02-15 2020-07-22 Seattle Genetics Inc Anticuerpos de glipicano 3 y conjugados de los mismos
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
EP3892280A3 (en) 2020-04-09 2022-01-12 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
JP2023549872A (ja) 2020-11-18 2023-11-29 アストラゼネカ・アクチエボラーグ ステロイド節約
EP4312597A4 (en) * 2021-03-23 2025-01-22 Organogenesis, Inc. METHODS, KITS AND COMPOSITIONS FOR CHARACTERIZING AN ANTI-INFLAMMATORY RESPONSE OF A PRODUCT
KR20240114801A (ko) * 2023-01-17 2024-07-25 한양대학교 산학협력단 Il-10 수용체에 특이적으로 결합하는 항체 및 이의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH06505250A (ja) * 1991-01-16 1994-06-16 シェリング・コーポレーション 癌の養子免疫療法におけるインターロイキン−１０の使用
DE69233254T2 (de) * 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
US5833976A (en) 1991-08-06 1998-11-10 Schering Corporation Use of interleukin-10 (IL-10) to treat endotoxin- or superantigen-induced toxicity
ATE187336T1 (de) 1991-08-06 1999-12-15 Schering Corp Verwendung von interleukin-10 analogen oder antagonisten zur behandlung von endotoxin- oder superantigen induzierter toxizität
DE4425115A1 (de) * 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
DE19529026C2 (de) 1995-07-28 1997-06-19 Robert Sabat Monoklonale Antikörper gegen humanes Interleukin-10
RS20100366A (sr) 2002-12-16 2011-04-30 Genentech, Inc. Varijante imunoglobulina i njihova upotreba
PE20090046A1 (es) 2003-11-10 2009-01-26 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
NO2195023T3 (es) * 2007-08-29 2018-08-04
NZ600899A (en) 2009-11-30 2014-09-26 Biotest Ag Humanized anti-il-10 antibodies for the treatment of systemic lupus erythematosus (sle)

Also Published As

Publication number Publication date
EP2470209B1 (en) 2020-01-01
IL219954A (en) 2016-10-31
US20120321618A1 (en) 2012-12-20
CA2782007C (en) 2018-07-24
WO2011064398A1 (en) 2011-06-03
US20120321617A1 (en) 2012-12-20
US20150064179A1 (en) 2015-03-05
WO2011064399A1 (en) 2011-06-03
IL219955A0 (en) 2012-07-31
RU2587622C2 (ru) 2016-06-20
US8956607B2 (en) 2015-02-17
BR112012012917A2 (pt) 2016-10-25
CN102811736B (zh) 2016-01-20
CO6561779A2 (es) 2012-11-15
KR20120115289A (ko) 2012-10-17
MX350206B (es) 2017-08-28
US9605066B2 (en) 2017-03-28
SG10201407936XA (en) 2015-01-29
EP2470208A1 (en) 2012-07-04
CN102711829B (zh) 2016-03-16
RU2012127380A (ru) 2014-01-10
RU2581812C2 (ru) 2016-04-20
US9540436B2 (en) 2017-01-10
MX2012006198A (es) 2012-06-19
NZ600894A (en) 2014-09-26
JP2013511995A (ja) 2013-04-11
ZA201204843B (en) 2020-02-26
AU2010323037A1 (en) 2012-07-19
CN102811736A (zh) 2012-12-05
MX2012006197A (es) 2012-06-19
BR112012012912A2 (pt) 2016-10-25
MX343228B (es) 2016-10-26
CA2782004A1 (en) 2011-06-03
SG10201407935YA (en) 2015-01-29
AU2010323036B2 (en) 2015-01-29
CR20120358A (es) 2013-01-23
US20150218270A1 (en) 2015-08-06
IL219955A (en) 2016-08-31
AU2010323037B2 (en) 2015-01-29
IL219954A0 (en) 2012-07-31
JP2013511994A (ja) 2013-04-11
JP6005519B2 (ja) 2016-10-12
KR101802261B1 (ko) 2017-11-28
US8852871B2 (en) 2014-10-07
EP2470209A1 (en) 2012-07-04
KR101802260B1 (ko) 2017-11-28
AU2010323036A1 (en) 2012-07-19
CN102711829A (zh) 2012-10-03
NZ600899A (en) 2014-09-26
KR20120103664A (ko) 2012-09-19
CA2782007A1 (en) 2011-06-03
RU2012127381A (ru) 2014-01-10

Similar Documents

Publication Publication Date Title
CR20120359A (es) Anticuerpos anti-il-10 humanizados para el tratamiento de lupus sistemico eritematoso (sle)
NZ607969A (en) Cd33 binding agents
PT2552955T (pt) Anticorpos com afinidade modificada para fcrn que promovem a depuração de antigénios
NZ598713A (en) Insulin receptor binding antibodies
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
WO2013188693A8 (en) Antigen binding constructs to cd3
BR112013020500A8 (pt) anticorpo isolado, recombinante ou purificado
NZ599140A (en) Antibodies that specifically bind to the epha2 receptor
TN2013000417A1 (en) Antibody polypeptides that antagonize cd40
MX2012002458A (es) Anticuerpos anti-cdcp1 humanizados.
EA201490454A1 (ru) Тернесит в качестве активатора для латентно-гидравлических и пуццолановых веществ
MY188469A (en) Low affinity blood brain barrier receptor antibodies and uses therefor
WO2009026117A3 (en) Novel compounds
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2009131702A3 (en) Antibodies against fcrn and use thereof
UY33703A (es) Anticuerpos anti-il-23
EA201300978A1 (ru) Антитела к сеа
PH12013502378A1 (en) Fc RECEPTOR BINDING PROTEINS
MX2009008608A (es) Anticuerpos monoclonales anti-cxcl13.
BRPI0809665B8 (pt) anticorpo monoclonal que se liga especificamente a endosialina
MX365387B (es) Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EA201291065A1 (ru) Антитела против vla-4